ASAM Provider Guide

National Practice Guideline

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1019954

Contents of this Issue

Navigation

Page 16 of 23

15 Î Care for pregnant women with OUD should be co-managed by an obstetrician and an addiction specialist physician. • Release of information forms need to be completed to ensure communication among health care providers. Î Clinicians should be aware that the pharmacokinetics of methadone are affected by pregnancy. • With advancing gestational age, plasma levels of methadone progressively decrease and clearance increases. Increased or split doses may be needed as pregnancy progresses. After child birth, doses may need to be adjusted. Î Buprenorphine monoproduct is a reasonable and recommended alternative to methadone for pregnant women. • While there is evidence of safety, there is insufficient evidence to recommend the combination buprenorphine/naloxone formulation. Î If a woman becomes pregnant while she is receiving naltrexone, it is appropriate to discontinue the medication if the patient and doctor agree that the risk of relapse is low. • If the patient is highly concerned about relapse and wishes to continue naltrexone, she should be informed about the risks of staying on naltrexone and provide her consent for ongoing treatment. • If the patient wishes to discontinue naltrexone but then reports relapse to opioid use, it may be appropriate to consider treatment with methadone or treatment with buprenorphine. Î Naloxone is NOT recommended for use in pregnant women with OUD except in situations of life threatening overdose. Î Mothers receiving methadone and buprenorphine monoproduct for the treatment of OUDs should be encouraged to breastfeed. Individuals with Pain Î For all patients with pain, it is important that the correct diagnosis be made and that a target suitable for treatment is identified. Î If pharmacological treatment is considered, nonnarcotic medications such as acetaminophen and NSAIDs should be tried first. Î Opioid agonists (methadone or buprenorphine) should be considered for patients with active OUD who are not in treatment. Î Pharmacotherapy in conjunction with psychosocial treatment should be considered for patients with pain who have OUD. Î Patients on methadone for the treatment of OUD will require doses of opioids in addition to their regular daily dose of methadone to manage acute pain.

Articles in this issue

Archives of this issue

view archives of ASAM Provider Guide - National Practice Guideline